

# DEVELOPING A REAL-TIME PCR PROCEDURE FOR DETECTING D842V MUTATION OF THE *PDGFRA* GENE IN GASTROINTESTINAL STROMAL TUMORS (GIST)

Nguyen Ngoc My Quynh, Nguyen Thanh Truc, Nguyen Hung Thinh, Nguyen Huu Ngoc Tuan

## INTRODUCTION

Mutations in *PDGFRA* exon 18, especially D842V, are a major cause of resistance to Imatinib in GISTs. A reliable, cost-effective diagnostic tool for detecting the D842V mutation is needed in clinical practice. Real-time PCR (qPCR) offers a feasible solution due to its efficiency, reliability, and high sensitivity. This study aims to: (1) optimize primer design; (2) create a positive control plasmid; and (3) establish a SYBR Green qPCR protocol to detect the D842V mutation. The results will help clinicians select appropriate treatments, particularly Gleevec (Imatinib), and may improve outcomes for GIST patients.

## MATERIAL & METHODOLOGY

15 cases with a confirmed pathological diagnosis of GIST HCMCOH from January 2021 to June 2023.

Specific primers targeting the mutation at position 842 (D to V) were designed using primer-BLAST (NCBI) (**Figure 1**), and primer concentration and annealing temperature were optimized.

A plasmid carrying the D842V mutation of the *PDGFRA* gene was created and used as a positive control to validate the quality of the SYBR Green real-time PCR assay.

The developed assay was applied to the 15 samples, which were previously assessed by Sanger sequencing.



**Figure 1.** The optimal results of the primer for detecting the D842V mutation in exon 18 of the *PDGFRA* gene

## CONCLUSION

The SYBR Green real-time PCR assay for detecting the D842V mutation of the *PDGFRA* gene in GIST patients can be routinely applied to assist clinicians in determining appropriate Gleevec (Imatinib) treatment for GIST patients.

## REFERENCE

- [1] Cassier, P.A., Fumagalli, E., Rutkowski, P., Schöffski, P., Van Glabbeke, M., Debiec-Rychter, M., et al. (2012), "Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era", *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research*, 18 (16), pp. 4458–4464.
- [2] Du, Z.-Q., Dong, J., Li, M.-X., Zhang, J.-F., Bi, J.-B., Ren, Y.-F., et al. (2020), "Overexpression of Platelet-Derived Growth Factor Receptor A D842V Mutants Prevents Liver Regeneration and Chemically Induced Hepatocarcinogenesis via Inhibition of MET and EGFR", *Journal of Cancer*, 11 (15), pp. 4614–4624.
- [3] Paulsson, J., Ehnman, M., and Östman, A. (2014), "PDGF receptors in tumor biology: prognostic and predictive potential", *Future Oncology (London, England)*, 10 (9), pp. 1695–1708.
- [4] Rizzo, A., Pantaleo, M.A., Astolfi, A., Indio, V., and Nannini, M. (2021), "The Identity of *PDGFRA* D842V-Mutant Gastrointestinal Stromal Tumors (GIST)", *Cancers*, 13 (4), pp. 705.

## RESULTS & DISCUSSION


A successful protocol was established to detect the D842V mutation in exon 18 of the *PDGFRA* gene using Sanger sequencing and SYBR Green real-time PCR, creating a valuable tool for the diagnosis and treatment of GIST.

Constructing a DNA plasmid with the D842V mutation as a positive control helps ensure the sensitivity, specificity, and accuracy of the real-time PCR assay. (**Figure 2**).


The analysis of 15 GIST FFPE samples to detect the D842V mutation in exon 18 of the *PDGFRA* gene using SYBR Green real-time PCR showed negative results, consistent with data from the Sanger sequencing method (**Table 1, Figure 3**).

Result	SYBR Green qPCR	Sanger sequencing
Mutation	0	15
No Mutation	15	0
Total	15	15

**Table 1.** The distribution of SYBR Green real-time PCR results and Sanger sequencing analysis.



**Figure 2.** The Sanger sequencing results of the DNA plasmid containing the D842V mutation, used as a positive control.



**Figure 3.** *PDGFRA* exon 18 sequence with good signals and no mutation.